UNSPSC 51182213: Meteneprost

This classification denotes a prostaglandin analogue with the molecular formula C23H38O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 269EB4R1TV, chemically known as 9-methylene-11r,15s-dihydroxy-16,16-dimethyl-5z,13e-prostadienoic acid but generally known as meteneprost, which bears US NIH Compound Identifier 5283060. European Medicines Agency schedules Meteneprost in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08822MIG.

UNSPSC 51182213 Meteneprost is a Commodity code that encompasses pharmaceutical products supplied through multistate cooperative purchasing alliances to state and local government facilities. State and local agencies procure meteneprost and related pharmaceuticals as part of broader generic multi-source drug and over-the-counter product frameworks rather than as standalone line items. The solicitations under this code originate from state departments of administration and cooperative purchasing organizations serving multiple jurisdictions—notably multistate alliances like the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP)—rather than individual counties or municipalities. Vendors responding to these opportunities must meet stringent regulatory and contractual requirements, including cGMP and DSCSA compliance, contractual relationships with authorized wholesalers (AmerisourceBergen, Cardinal Health, and Morris & Dickson), EDI capability, commercial general liability coverage of at least $5 million per occurrence, and performance standards that carry financial penalties ranging from $200 to $1,500 per violation for issues including late reporting and missed onboarding timelines.

MMCAP, administered by the Minnesota Department of Administration's Office of State Procurement, issued a Request for Proposal on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic pharmaceuticals and OTC products to be distributed across participating state and local facilities, including Oregon. Award decisions will weight price competitiveness at 75 percent, with the remaining evaluation split across fixed pricing, administrative compliance, EDI capability, and fee structure. All products must be available by May 15, 2026, with contract effectiveness set for July 1, 2026. Vendors should expect to pay a 3 percent administrative fee on contract purchases, and contract terms run two years for new vendors with optional extensions at MMCAP's sole discretion, while incumbent vendor amendments align with existing expiration dates through June 30, 2028. No specific dollar values or budget ranges are disclosed in the solicitation.